These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26420448)

  • 1. High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles.
    Baiu DC; Artz NS; McElreath MR; Menapace BD; Hernando D; Reeder SB; Grüttner C; Otto M
    Nanomedicine (Lond); 2015 Oct; 10(19):2973-2988. PubMed ID: 26420448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma.
    Vavere AL; Butch ER; Dearling JL; Packard AB; Navid F; Shulkin BL; Barfield RC; Snyder SE
    J Nucl Med; 2012 Nov; 53(11):1772-8. PubMed ID: 23064212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
    Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F
    Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing both CT imaging and natural killer cell-mediated cancer cell killing by a GD2-targeting nanoconstruct.
    Jiao P; Otto M; Geng Q; Li C; Li F; Butch ER; Snyder SE; Zhou H; Yan B
    J Mater Chem B; 2016 Jan; 4(3):513-520. PubMed ID: 27087966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linker-free conjugation and specific cell targeting of antibody functionalized iron-oxide nanoparticles.
    Xu Y; Baiu DC; Sherwood JA; McElreath MR; Qin Y; Lackey KH; Otto M; Bao Y
    J Mater Chem B; 2014 Oct; 2(37):6198-6206. PubMed ID: 26660881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen.
    Förster-Waldl E; Riemer AB; Dehof AK; Neumann D; Brämswig K; Boltz-Nitulescu G; Pehamberger H; Zielinski CC; Scheiner O; Pollak A; Lode H; Jensen-Jarolim E
    Mol Immunol; 2005 Feb; 42(3):319-25. PubMed ID: 15589320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody.
    Wang CH; Huang YJ; Chang CW; Hsu WM; Peng CA
    Nanotechnology; 2009 Aug; 20(31):315101. PubMed ID: 19597244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hu14.18K.322A Causes Direct Cell Cytotoxicity and Synergizes with Induction Chemotherapy in High-Risk Neuroblastoma.
    Thomas M; Nguyen TH; Drnevich J; D'Souza AM; de Alarcon PA; Gnanamony M
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma.
    Goldberg JL; Navid F; Hank JA; Erbe AK; Santana V; Gan J; de Bie F; Javaid AM; Hoefges A; Merdler M; Carmichael L; Kim K; Bishop MW; Meager MM; Gillies SD; Pandey JP; Sondel PM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictable Heating and Positive MRI Contrast from a Mesoporous Silica-Coated Iron Oxide Nanoparticle.
    Hurley KR; Ring HL; Etheridge M; Zhang J; Gao Z; Shao Q; Klein ND; Szlag VM; Chung C; Reineke TM; Garwood M; Bischof JC; Haynes CL
    Mol Pharm; 2016 Jul; 13(7):2172-83. PubMed ID: 26991550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands.
    Fiandra L; Mazzucchelli S; De Palma C; Colombo M; Allevi R; Sommaruga S; Clementi E; Bellini M; Prosperi D; Corsi F
    ACS Nano; 2013 Jul; 7(7):6092-102. PubMed ID: 23758591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.
    Eger C; Siebert N; Seidel D; Zumpe M; Jüttner M; Brandt S; Müller HP; Lode HN
    PLoS One; 2016; 11(3):e0150479. PubMed ID: 26967324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Neuroblastoma Activity of Gold Nanorods Bound with GD2 Monoclonal Antibody under Near-Infrared Laser Irradiation.
    Peng CA; Wang CH
    Cancers (Basel); 2011 Jan; 3(1):227-40. PubMed ID: 24212615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
    Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
    Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current limitations of molecular magnetic resonance imaging for tumors as evaluated with high-relaxivity CD105-specific iron oxide nanoparticles.
    Dassler K; Roohi F; Lohrke J; Ide A; Remmele S; Hütter J; Pietsch H; Pison U; Schütz G
    Invest Radiol; 2012 Jul; 47(7):383-91. PubMed ID: 22659596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.